Aspirin and Colon Cancer: Daily Dose May Reduce Risk, Studies Show

A major new review of clinical evidence concludes that daily aspirin does not reliably prevent colorectal cancer in people at average risk, challenging long-held assumptions about the drug’s role in cancer prevention.

The analysis, conducted by researchers at West China Hospital of Sichuan University in China, examined data from 10 randomized controlled trials involving 124,837 participants. It found no consistent protective effect of aspirin against bowel cancer in the general population, with any potential benefit requiring more than a decade to emerge—if it occurs at all—and supported by weak evidence.

In contrast, the risk of serious gastrointestinal bleeding begins immediately with regular aspirin use, even at low doses. Experts emphasize that the harms of aspirin are well-established and occur from the first day of use, while any possible cancer prevention benefit remains uncertain and delayed.

“Daily aspirin isn’t a guaranteed cancer guard — and it comes with real risks from day one,” stated the Cochrane review’s summary. The findings underscore that prevention decisions should be individualized rather than based on blanket recommendations, particularly given the availability of proven strategies such as healthy lifestyle choices and routine screening.

Colorectal cancer remains one of the most common cancers globally. While earlier research had explored whether widely available medications like aspirin might reduce risk, this latest review adds to growing uncertainty about its effectiveness for prevention in average-risk individuals.

Other recent studies have presented more nuanced findings. A Harvard-affiliated study published in JAMA Oncology, which followed over 100,000 men and women for 30 years, suggested that regular aspirin use may lower colorectal cancer risk in individuals with less-healthy lifestyles, who appeared to benefit the most. However, this benefit was observed in a specific subgroup and does not apply broadly to the general population.

clinical trials have indicated that aspirin may reduce the risk of cancer recurrence in certain patients with existing colorectal cancer. Research presented by the American Society of Clinical Oncology (ASCO) found that daily treatment with 160 mg of aspirin for three years reduced recurrence rates in patients with stage I, II, or III rectal cancer or stage II or III colon cancer who have specific genetic alterations in the PI3K signaling pathway—present in about one-third of colorectal cancer cases.

These findings highlight that aspirin’s potential role in colorectal cancer may be limited to specific contexts, such as secondary prevention in genetically defined subgroups, rather than broad primary prevention in the general population.

The U.S. Preventive Services Task Force previously recommended daily low-dose aspirin for adults aged 50 to 59 to prevent both cardiovascular events and colorectal cancer. However, in 2022, it revised its guidance to focus solely on cardiovascular disease prevention, citing insufficient evidence for aspirin’s role in preventing colorectal cancer and calling for further research.

An expanded meta-analysis of cardiovascular prevention trials has also noted a 21% lower risk of all-cancer death associated with daily aspirin use at any dose, though this finding does not isolate colorectal cancer specifically and may reflect broader effects unrelated to direct anti-tumor activity.

Given the immediate risks of bleeding and the lack of reliable evidence for timely cancer prevention in average-risk individuals, medical experts advise against routine aspirin use solely for colorectal cancer prevention. Instead, they recommend personalized decisions based on individual risk factors, family history, and consultation with healthcare providers.